Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy

Francesco Paolo Tambaro; Sajad Khazal; Cesar Nunez; Dristhi Ragoonanan; Priti Tewari; Demetrios Petropoulos; Partow Kebriaei; William George Wierda; Kris Michael Mahadeo

doi:10.1002/ccr3.2918

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy

Clin Case Rep. 2020 May 28;8(9):1678-1681. doi: 10.1002/ccr3.2918. eCollection 2020 Sep.

Authors

Francesco Paolo Tambaro^{1

2}, Sajad Khazal¹, Cesar Nunez³, Dristhi Ragoonanan³, Priti Tewari¹, Demetrios Petropoulos¹, Partow Kebriaei⁴, William George Wierda⁵, Kris Michael Mahadeo¹

Affiliations

¹ Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer Center Children's Cancer Hospital Houston Texas USA.
² Bone Marrow Transplant Unit Pediatric Oncology Department AORN Santobono Pausilipon Naples Italy.
³ Department of Pediatrics The University of Texas MD Anderson Cancer Center Children's Cancer Hospital Houston Texas USA.
⁴ Department of Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer Center Houston Texas USA.
⁵ Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA.

Abstract

The T-cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T-cell therapy.

Keywords: acute lymphoblastic leukemia; blinatumomab; chimeric antigen receptor.

Publication types

Case Reports